A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 591 participants.
Also called NCT04809220
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 591 participants
- Sponsor
- Registry
-
NCT04809220
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT04809220. Randomized; double masking; primary purpose treatment. Start 2021-04-13 (actual); primary completion 2022-10-01 (actual). Results posted on 2023-09-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
- Acronym
- AWARD-JPN
- Condition
- Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Glucose Metabolism Disorders
- Condition
- Metabolic Disease
- Condition
- Endocrine System Diseases
- Condition
- Hypoglycemic Agents
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Oral antihyperglycemics
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04809220- Content hash
f507ad19cc5c206d4e0bd7bc56eae4dbc35bb27776578d39481e67ecd14ba654